ILT3 Polypeptides and Uses Thereof
AssigneeThe Trustees of Columbia University in the City of New York
InventorsNicole Suciu-Foca, George Vlad, Raffaello Cortesini
Life of this patent
Estimating the term…
Abstract
This invention provides a method for inhibiting the rejection of transplanted islet cells, comprising administering to the subject a polypeptide comprising all or a portion of the extracellular domain of ILT3, wherein the polypeptide is water soluble. This invention further provides a method of treating diabetes, by inhibiting the rejection of transplanted islet cells through the administration of the polypeptide to the subject.
Claims36
A method of inhibiting the onset of transplant rejection in a subject who has received, or is about to receive, an islet cell transplant, the method comprising the step of administering to the subject a therapeutically effective amount of a polypeptide comprising all or a portion of the extracellular domain of ILT3.
A method of treating diabetes by inhibiting islet cell transplant rejection in a subject, the method comprising the step of administering to the subject a therapeutically effective amount of a polypeptide comprising all or a portion of the extracellular domain of ILT3.
A method of treating, delaying the onset of, inhibiting or preventing graft versus host disease in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a polypeptide comprising all or a portion of the extracellular domain of ILT3.
Dependencies are inferred from the claim text.